Stevanato Group (STVN) shares jump after 2026 outlook leans on GLP-1 drug packaging
Stevanato forecast 2026 revenue of €1.26–€1.29 billion and adjusted EBITDA of €331.8–€346.9 million. GLP-1-related products accounted for about 19–20% of 2025 revenue. U.S.-listed shares rose 18.8% to $17.50 after the update. Fourth-quarter revenue increased 5% to €346.5 million, with net profit at €47.6 million.